You are here

BCRF Grantee Since

2002

Donor Recognition

The Hamptons Paddle & Party for Pink Award

Robert J. Schneider, PhD

Associate Dean, Office of Therapeutic Alliances
Associate Director, NYU Cancer Institute
Co-Director, Breast Cancer and Translational Cancer Research
Albert B. Sabin Professor of Molecular Pathogenesis
NYU School of Medicine
New York, New York

Current Research

Most women who die of breast cancer die from metastatic disease, the spread of tumor cells to different parts of the body. There are currently no curative therapies for metastatic breast cancer. The major goal of Dr. Schneider’s BCRF research is to develop effective treatments for this disease. Work from his laboratory has shown that metastasis of breast cancer requires specific reprogramming of the protein synthesis machinery of breast cancer cells by a protein called mTOR. His research team is focused on developing new therapeutic drugs as inhibitors of mTOR to prevent metastasis. They have also initiated research to identify specific genetic changes in metastatic tumors that sensitize them to these inhibitors in order to identify those women who most likely to benefit from these new drugs.

Bio

Dr. Robert Schneider is the Albert Sabin Professor of Molecular Pathogenesis at NYU School of Medicine, an Associate Director of the NYU Cancer Institute, Breast Cancer Program Co-Director and Associate Dean for the Office of Therapeutics and Industry Alliances. He has published more than 140 peer reviewed papers. His research is directed to the development, progression and metastasis of breast cancer and the interplay of the inflammatory response, and the development of new therapeutics for metastatic breast cancer. Dr. Schneider has received numerous awards and prizes in recognition of his research, including the 2010 Judah Folkman Memorial lecture; the 2011 Distinguished Alumnus Award & Commencement address, University of Delaware and the 2012 Susan E. Donelan Hope for the Future Award for breast cancer research, Dana Farber Cancer Institute. Dr. Schneider is a founding scientist of five biotechnology companies focused on translating oncology research to the clinic.